Episode summary
AT&T to Buy EchoStar Spectrum Licenses for About $23 Billion | Bloomberg Intelligence
Bloomberg Intelligence
· · 23 min · Hosts: Lisa Mateo, Alexis Christoforous · Guests: John Butler, Sam Fazeli, Diana Gomes, Patricio Alvarez
Summary
EchoStar’s agreement to sell spectrum licenses to AT&T for about $23 billion was the biggest market-moving story in the episode. The host said EchoStar shares jumped 77%, and Bloomberg Intelligence senior telecom analyst John Butler argued the deal sharply reduces EchoStar’s bankruptcy risk by relieving its debt pressure and satisfying FCC pressure to either use or sell the spectrum. He also said this may not be the last spectrum sale if EchoStar keeps monetizing assets.
Butler said AT&T is not overpaying because spectrum tends to rise in value, especially as AI increases network traffic and demand for capacity. He said AT&T plans to put the airwaves to work quickly to improve download speeds, strengthen its network brand, and prepare for more edge computing traffic. On regulation, he said the FCC appears to have encouraged the sale and that he does not expect a serious antitrust or spectrum-concentration challenge.
The show also covered Eli Lilly’s obesity pill data, with Sam Fazeli saying the oral drug produced about 10% weight loss in obese diabetic patients and may be especially useful for patients who dislike injections or need a maintenance option after injectable treatment. Diana Gomes said EssilorLuxottica may raise its Nikon stake from about 9% to around 20% to support smart glasses and eye-care technologies. Patricio Alvarez said Orsted’s stop-work order on its near-finished Rhode Island wind farm could shake investor confidence, but Danish government backing may still let its equity raise proceed.
Key takeaways
- John Butler said EchoStar’s $23 billion spectrum sale materially lowers default risk by easing its capital crunch and debt burden.
- Butler said AT&T is buying capacity it can use immediately, and that AI traffic makes spectrum more valuable over time.
- Sam Fazeli said Eli Lilly’s oral obesity drug produced about 10% weight loss in obese diabetic patients, with pills appealing as an easier-to-use alternative to injections.
- Fazeli said the pill could fit as a maintenance therapy after injectable weight-loss drugs and may help patients who cannot access injectables.
- Diana Gomes said EssilorLuxottica may lift its Nikon stake from about 9% to around 20% to deepen work on smart glasses and myopia-control lenses.
- Patricio Alvarez said Orsted’s planned equity raise is still likely to proceed because the Danish government has committed to a 50.1% share.
Notable quotes
“it is huge for Echoar and I think that issue for them is they have they've been trying to build their own 5G network to compete with the big guys”
“any risk of default here, I think, is minimized now in the wake of this deal”
“Spectrum is like houses on Nantucket. you know, the the price just continues to go up over the years”
“the more you have, think of it like the width of a pipe. The more you have, the fatter the pipe, the faster the download speeds”
“we're seeing about 10% weight loss and um still the same high levels of uh discontinuations”
How the episode opens
Bloomberg Audio Studios, podcasts, radio, news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business App.
Listen on demand wherever you get your podcasts or watch us live on YouTube. Okay, so we have some big news. Echoar, it's agreed to sell Spectrum licenses to AT&T for about $23 billion.
I'm looking at Echoar shares right now. They're up 77%. So, we wanted to talk about this, right?
So, our producers are scrambling. It's a mad dash. Who are we going to get?
We're going to pull in someone who's hanging in Nantucket. That's right. It's John Butler, Bloom Intelligence, senior telecom analyst.
John, we really appreciate you taking the time for us.
No problem. Good morning, guys. How are you? — Good morning. Yes, we pulling the big guns. So, so explain to us right off the bat what does this deal mean?
So, obviously given the price action, it is huge for Echoar and I think that issue for them is they have they've been trying to build their own 5G network to compete with the big guys and they have the spectrum to do it but they didn't have the capital to do it. they really have an outsized debt load that they've really been struggling to service and um the FCC intervened here and they've been pressuring um uh the head of Echoar Charlie Urggon to either use the spectrum and start to fill those airwaves or to sell it. And so I think this is maybe the first of maybe even more moves to sell more spectrum on the part of the company.
But given the price tag, it alleviates that capital crunch. And so any risk of default here, I think, is minimized now in the wake of this deal.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- spectrum deal
- telecom bankruptcy risk
- obesity drug trial
- eyewear and nikon stake
- offshore wind construction halt
Companies and tickers mentioned
- T
- SATS
- LLY
- ELUXY
- NINOY
- DNNGY
- AT&T Inc.
- EchoStar
- Eli Lilly & Co.
- EssilorLuxottica
- Nikon Corp.
- Orsted
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Anthropic’s IPO Is Said to Be About Six Times Oversubscribed | Bloomberg Intelligence -
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
